Structure-based design of macrocyclic factor XIa inhibitors: Discovery of the macrocyclic amide linker

JR Corte, T Fang, H Osuna, DJP Pinto… - Journal of Medicinal …, 2017 - ACS Publications
… Introduction of the amide moiety into the 12-membered macrocyclic linker 22 increased the
… The amide moiety, which led to a significant improvement in terms of both FXIa activity and …

Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability

CG Clark, KA Rossi, JR Corte, T Fang… - Bioorganic & Medicinal …, 2019 - Elsevier
inhibitors with cyclic P1 linkers was designed based on the X-ray crystal structure of 1. By
constraining the P1 linker … , while removing the tetrazole moiety and acrylamide proton, both …

Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency

JR Corte, W Yang, T Fang, Y Wang, H Osuna… - Bioorganic & Medicinal …, 2017 - Elsevier
… , between the NH of the amide moiety in the macrocyclic linker and the carbonyl of Leu41 in
… that the alkyl backbone of the macrocyclic amide linker did not fully access the hydrophobic …

Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties

DJP Pinto, JM Smallheer, JR Corte, EJD Austin… - Bioorganic & Medicinal …, 2015 - Elsevier
… The m-chlorophenyl P1 moiety is orthogonal to the urea linker, with the urea carbonyl oriented
directly into the oxyanion hole and capable of forming strong hydrogen bond interactions …

Structure-based design and preclinical characterization of selective and orally bioavailable factor XIa inhibitors: demonstrating the power of an integrated S1 protease …

E Lorthiois, J Roache, D Barnes-Seeman… - Journal of medicinal …, 2020 - ACS Publications
… We then focused on the linker between the S1β and the prime site with an aim to enhance
… of a polar moiety could introduce additional conformational bias in the linker and lower the …

Studies on fragment-based design of allosteric inhibitors of human factor XIa

RS Boothello, NV Sankaranarayanan… - Bioorganic & medicinal …, 2020 - Elsevier
… We also show that certain related linkers, eg, more rigid, aromatic linkers, are not preferred,
which points to the interesting landscape of heparin-binding site of hFXIa. Overall, this work …

Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa

T Fang, JR Corte, PJ Gilligan, Y Jeon, H Osuna… - Bioorganic & Medicinal …, 2020 - Elsevier
… Since efforts to reduce PSA in the P2 prime region led to a loss in both FXIa affinity and
metabolic stability, we turned our attention to modifying the amide moiety in the macrocyclic linker

Discovery of a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species

W Yang, Y Wang, A Lai, CG Clark… - Journal of Medicinal …, 2020 - ACS Publications
… Oral factor XIa (FXIa) inhibitors may provide a promising new … cyclic carbamate P1 linker
which provided improved oral … imidazole core as well as various linkers to the P1 group led …

Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site

R Karuturi, RA Al-Horani, SC Mehta… - Journal of medicinal …, 2013 - ACS Publications
moiety on an otherwise identical base scaffold. Both inhibitors contain a minimum of 10
linker atoms, yet the additional triazole of 28S is likely to impart significant rigidity to the linker in …

Triazol: a privileged scaffold for proteolysis targeting chimeras

LW Xia, MY Ba, W Liu, W Cheng, CP Hu… - Future medicinal …, 2019 - Taylor & Francis
… triazole moiety as a privileged scaffold in the interval linker for … By switching the alkyl linker
to PEG and other linkers, other … inhibitors coupled with the thalidomide family moiety were …